Laura Poliseno

Dr. Laura Poliseno received her doctorate in Molecular Biotechnology from the University of Pisa, Italy. She has worked as a postdoctoral researcher at Memorial Sloan-Kettering and at Beth Israel Deaconess Medical Center, later starting a second post doc fellowship at NYU Langone. Laura is currently a Principal Investigator within the Oncogenomics unit at ISPRO and a researcher at the Institute of Clinical Physiology of the National Research Council in Pisa. Dr. Poliseno’s research has mostly been centered on non-coding RNAs (miRNA, pseudogenes, ceRNAS) and their respective roles in cancer. Recently, her lab has studied the coding and non-coding genetic network that regulates the BRAF and ERK kinase pathways in melanoma. Specifically, the inhibitory effects of the miR-204/miR-211 miRNAs on the BRAF pathway as a potential onco-suppresive agent. She has also studied the use of an attenuated L. monocytogenes, Lm(at)-LLO, as an antitumor agent potentially combining the effects of targeted and immunotherapeutic techniques. Dr. Poliseno aims to translate her findings in in vitro/in vivo melanoma models for related therapies.

Lab Information

Institute of Clinical Physiology of the National Research Council

Research Area and Skills

Recognize this scientist’s Expertise for their contribution in your research

Genomics 1 Functional Genetics 0 Non-coding RNA 0 Proteins and Human Diseases 0 Yeast Genetics and Genomics 1 Melanoma 0 Cardiovascular Diseases 1 Cancer Research 0

More

  • Post
  • Publication
  • Plasmid
  • Following (0)
  • Follower (5)


This guy hasn’t posted anything yet.

Hot Posts for You

The increasing number of confirmed COVID-19 cases is prompting an unprecedented global effort to find a treatment for the disease. Given the fact that a new drug development could be a decade work from initial discovery to the marketplace, scientists are racing to search a cure ...Learn More


The previous article on precision medicine was focused on Pharmacogenomics as a fundamental aspect of cancer therapeutics. In this sequel, emphasis would be on the role of immuno-oncology in personalization of cancer therapy, citing anti PD therapy as an example with hypothetical ...Learn More


IntroductionA gleam of light finally shone down on the global crisis of the prolonged battle against COVID-19, giving people hopes of preventive care and treatment in the near future by monoclonal antibodies against SARS-CoV-2. As stated the news of NIH’s phase III clinical ...Learn More


"Those who do not know history are obliged to repeat it" This famous phrase that could be from any history teacher to his suspended students has been attributed to great figures in history such as Napoleon or the philosopher George Santayana. In a modern version of it we could say ...Learn More


In recent years there is an increasing number of cytotoxic chemotherapeutic compounds with the ability to rapidly kill dividing cancer cells in preference to non-dividing healthy cells. Nevertheless, the major drawback of chemotherapy is that, in addition to damaging the cancer ...Learn More


The coronavirus pandemic caught everyone unprepared. We had to deal with the fear of an unknown virus which can be lethal for some people. And the whole world just stopped in an attempt to prevent the virus spread.Suddenly we had to adapt to a new way of living, socially isolated ...Learn More


  1. Lubrano, S., Comelli, L., Piccirilli, C., Marranci, A., Dapporto, F., Tantillo, E., Gemignani, F., Gutkind, J.S., Salvetti, A., Chiorino, G., Cozza, G., Chiariello, M., Galli, A., Poliseno, L., Cervelli, T. (2019). Development of a yeast-based system to identify new hBRAFV600E functional interactors. Oncogene, 38:1355-1366.

  2. Vitiello, M., Evangelista, M., Di Lascio, N., Kusmic, C., Massa, A., Orso, F., Sarti, S., Marranci, A., Rodzik, K., Germelli, L., Chandra, D., Salvetti, A., Pucci, A., Taverna, D., Faita, F., Gravekamp, C., Poliseno, L. (2019). Antitumoral effects of attenuated Listeria monocytogenes in a genetically engineered mouse model of melanoma. Oncogene.

  3. Marranci, A., Jiang, Z., Vitiello, M., Guzzolino, E., Comelli, L., Sarti, S., Lubrano, S., Franchin, C., Echevarría-Vargas, I., Tuccoli, A., Mercatanti, A., Evangelista, M., Sportoletti, P., Cozza, G., Luzi, E., Capobianco, E., Villanueva, J., Arrigoni, G., Signore, G., Rocchiccioli, S., Pitto, L., Tsinoremas, N., Poliseno, L. (2017). The landscape of BRAF transcript and protein variants in human cancer. Molecular Cancer, 16(1):85.

  4. Vitiello, M., Tuccoli, A., D’Aurizio, R., Sarti, S., Giannecchini, L., Poliseno, L., et al. (2017). Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells. Oncotarget, 8(15): 25395-25417.


This guy has no following anyone.

Popular Cloud Scientists

Cloud Scientists
  • Beate Escher photo

    Beate Escher

    Helmholtz Centre for Environmental Research–UFZ

  • Dimitri Kullmann photo

    Dimitri Kullmann

    UCL Queen Squaree Institute of Neurology

  • Changhao Bi photo

    Changhao Bi

    Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences

About Us · User Accounts and Benefits · Privacy Policy · Management Center · FAQs
© 2020 MolecularCloud